1 2 3 4 5

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

Stellbrink, Hans-Jürgen; Le Fevre, Eric; Carr, Andrew; More

AIDS . 30(8):1229-1238, May 15, 2016.

The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters

Martinez, Esteban; Visnegarwala, Fehmida; Grund, Birgit; More

AIDS . 24(3):353-563, January 28, 2010.

HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial

Calmy, Alexandra; Gayet-Ageron, Angèle; Montecucco, Fabrizio; More

AIDS . 23(8):929-939, May 15, 2009.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

Martin, Allison; Smith, Don E; Carr, Andrew; More

AIDS . 18(7):1029-1036, April 30, 2004.

Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV‐1‐infected individuals

Kaufmann, Gilbert R.; Duncombe, Chris; Cunningham, Philip; More

AIDS . 12(13):1625-1630, September 10, 1998.

Increased frequency of CCR‐5 Δ32 heterozygotes among long‐term non‐progressors with HIV‐1 infection

Stewart, Graeme J.; Ashton, Lesley J.; Biti, Robyn A.; More

AIDS . 11(15):1833-1838, December 11, 1997.

1 2 3 4 5